P600 Vedolizumab dose optimisation: Findings from a Belgian registry
Volume: 14, Issue: Supplement_1, Pages: S501 - S502
Published: Jan 1, 2020
Abstract
Background Vedolizumab (VDZ) dose optimisation (DO), by interval shortening from 8-weekly (Q8W) to 4-weekly (Q4W) dosing, is used for patients with secondary loss of response. This report presents outcome data on patients receiving DO in real-world clinical practice in Belgium. Methods The Belgian VDZ Registry (ENcePP EUPAS6469) enrolled 202 VDZ-treated ulcerative colitis (UC) or Crohn’s disease (CD) adult patients (26% with no prior use of...
Paper Details
Title
P600 Vedolizumab dose optimisation: Findings from a Belgian registry
Published Date
Jan 1, 2020
Volume
14
Issue
Supplement_1
Pages
S501 - S502
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History